Treatment with a VEGF monoclonal antibody has resulted in hearing improvement in patients with NF2-associated VS6, and delivery of siRNA against VEGF or HIF-1α to downregulate VEGF expression reduced glioma growth59. The gene discussed is VEGFA; the disease is central nervous system cancer.